コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ns (apolipoprotein B, total cholesterol, and non-high-density lipoprotein cholesterol).
2 ol, low density lipoprotein cholesterol, and non-high density lipoprotein cholesterol.
3 f cheese was inversely associated with serum non-high-density lipoprotein cholesterol.
4 associated with TGs, total cholesterol, and non-high-density lipoprotein cholesterol.
5 es of low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol.
6 ortality, provides significant reductions in non-high-density lipoprotein cholesterol.
7 B and low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol.
8 [95% CI, 8.0-12.8], respectively; P = .002), non-high-density lipoprotein cholesterol (-0.4% [95% CI,
9 .4%]), and combined hypertension, LDL-C, and non-high-density lipoprotein cholesterol (1.8% [95% CI,
10 ity lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%)
11 acid vs placebo were observed at week 12 for non-high-density lipoprotein cholesterol (-10.8% vs 2.3%
12 pg/mL), higher mean fasting serum levels of non-high-density lipoprotein cholesterol (126.5 and 121.
13 otal cholesterol (-24.8 mg/dl), atherogenic (non-high-density lipoprotein) cholesterol (-19.9 mg/dl),
14 mean (SD) apolipoprotein B (38.0% [22.1%]), non-high density lipoprotein cholesterol (48.4% [23.2%])
16 xposure, (4) sleep, (5) body mass index, (6) non-high-density lipoprotein cholesterol, (7) blood gluc
17 h-density lipoprotein-cholesterol, 12.0% for non-high-density lipoprotein-cholesterol, 8.0% for low-d
19 cholesterol (aHR, 1.38; 95% CI, 1.10-1.74), non-high-density lipoprotein cholesterol (aHR, 1.67; 95%
20 ol, high-density lipoprotein cholesterol, or non-high-density lipoprotein cholesterol, although trigl
21 olate diet for 3 mo had a 3-fold decrease in non-high-density lipoprotein cholesterol and a trend tow
22 largest trials of 4 g/d prescription n-3 FA, non-high-density lipoprotein cholesterol and apolipoprot
23 cribed for LDL-C were observed with achieved non-high-density lipoprotein cholesterol and apolipoprot
24 andomization identifies a negative effect of non-high-density lipoprotein cholesterol and associated
25 the associations of these foods with plasma non-high-density lipoprotein cholesterol and for red and
26 educational attainment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensit
27 y 1.6% or 1.4% after adjustment for LDL-C or non-high-density lipoprotein cholesterol and other covar
28 I, very low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipopro
29 d the relationship between additional LDL-C, non-high-density lipoprotein cholesterol, and apolipopro
30 low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, and apolipopro
31 Changes at week 88 in waist circumference, non-high-density lipoprotein cholesterol, and fasting in
33 y lipoprotein, high-density lipoprotein, and non-high-density lipoprotein cholesterol, and triglyceri
34 ed other atherogenic lipid levels, including non-high-density lipoprotein cholesterol, apolipoprotein
35 on lipid risk factors such as triglycerides, non-high-density lipoprotein cholesterol, apolipoprotein
36 ces were also observed in total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein
37 SAR236553 also substantially reduced non-high-density lipoprotein cholesterol, apolipoprotein
38 atin therapy have demonstrated reductions in non-high-density lipoprotein cholesterol as well as low-
39 ent for other cardiac risk factors including non-high-density lipoprotein cholesterol at 55 years of
40 ieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol but not vice ve
41 a cholesterol (by 40 and 57%, respectively), non-high density lipoprotein cholesterol (by 48 and 61%,
42 ed meat was positively associated with serum non-high-density lipoprotein cholesterol concentration a
43 icant decreases in mean apolipoprotein B and non-high-density lipoprotein cholesterol concentrations
44 fat diet for 10 wk showed a 40% increase in non-high-density lipoprotein cholesterol, consistent wit
45 ed with concomitant hypertension, LDL-C, and non-high-density lipoprotein cholesterol control (odds r
46 olesterol (LDL-C) (Delta = -7.0%; P = 0.01), non-high-density lipoprotein cholesterol (Delta = -2.5%;
47 s on low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in second
48 between duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol >/= 160 mg/dL)
49 ensity lipoprotein cholesterol >=70 mg/dL or non-high-density lipoprotein cholesterol >=100 mg/dL des
50 ipoprotein cholesterol (LDL-C) >=70 mg/dl or non-high-density lipoprotein cholesterol >=100 mg/dl to
51 rotein cholesterol (LDL-C) level >=70 mg/dl, non-high-density lipoprotein cholesterol >=100 mg/dl, or
52 ensity lipoprotein cholesterol (>=31 mg/dL), non-high-density lipoprotein cholesterol (>=145 mg/dL),
53 heart disease as well as serum elevations in non-high-density lipoprotein cholesterol (>=160 mg/dL) a
55 nged exposure to even moderate elevations in non-high-density lipoprotein cholesterol have elevated r
56 ncluded the triple goals of LDL-C <70 mg/dl, non-high-density lipoprotein cholesterol (HDL-C) <100 mg
57 erved, which was reflected in a reduction in non-high-density lipoprotein cholesterol (HDL-C) (125.3
58 .06, per 10 mg/dl [0.11 mmol/l]; p < 0.001), non-high-density lipoprotein cholesterol (HDL-C) (HR: 1.
59 iscordance between population percentiles of non-high-density lipoprotein cholesterol (HDL-C) and low
61 lycerides are >200 mg/dl, the measurement of non-high-density lipoprotein cholesterol (HDL-C) is reco
62 as a function of age, age at initiation, and non-high-density lipoprotein cholesterol (HDL-C) level o
63 rotein B (ApoB) levels did not increase, and non-high-density lipoprotein cholesterol (HDL-C) levels
65 ting low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol (HDL-C) levels
66 low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and ap
67 low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and tr
68 low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), HDL-C,
70 able effects on total plasma cholesterol and non-high-density lipoprotein cholesterol in KO, Het, and
71 ieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating tha
72 terol, high density lipoprotein cholesterol, non-high density lipoprotein cholesterol, insulin, or bo
74 al trials have examined the relation between non-high-density lipoprotein cholesterol level and cardi
75 tein cholesterol level of 70 to 189 mg/dL or non-high-density lipoprotein cholesterol level of 100 to
76 -C of at least 70 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at lea
78 After major improvements in lipid control (non-high-density lipoprotein cholesterol level, <130 mg
80 l LLT showed similar results in reduction of non-high-density lipoprotein cholesterol levels (49.0+/-
81 7.3%) vs. -5.3 mg/dL (-1.7%), P = 0.014] and non-high-density lipoprotein cholesterol levels [PA vs.
82 elevated blood pressure, hemoglobin A1c, or non-high-density lipoprotein cholesterol levels, and sel
83 tions in total, low-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in trig
84 ficantly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a)
85 dl for remnant cholesterol, and -8 mg/dl for non-high-density lipoprotein cholesterol; lipoprotein(a)
86 evels of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels o
87 lar events and control of 6 RFs (no smoking, non-high-density lipoprotein cholesterol <130 mg/dl, tri
88 14.94%; 95% CI -17.31%, -12.57%; p < 0.001), non-high-density lipoprotein cholesterol (MD -18.17%; 95
91 low-density lipoprotein cholesterol (-32%), non-high-density lipoprotein cholesterol (non-HDL-C) (-3
93 Education Program guidelines recommend that non-high-density lipoprotein cholesterol (non-HDL-C) be
94 ecreased apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) con
95 in clinical practice in children and adults, non-high-density lipoprotein cholesterol (non-HDL-C) has
97 n and low-density lipoprotein (LDL), whereas non-high-density lipoprotein cholesterol (non-HDL-C) lev
100 tein cholesterol (LDL-C), triglycerides, and non-high-density lipoprotein cholesterol (non-HDL-C) pre
102 -density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) wer
103 otein (LDL) impact the causal association of non-high-density lipoprotein cholesterol (non-HDL-C) wit
104 low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), an
105 s but also LDL-related biomarkers, including non-high-density lipoprotein cholesterol (non-HDL-C), ap
107 oremost markers, apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C), as
108 d population attributable fractions for SBP, non-high-density lipoprotein cholesterol (non-HDL-C), di
109 l youths, mean serum total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), hi
110 low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), hi
111 low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), or
112 is related to on-treatment apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), tr
113 secondary outcomes were effects on levels of non-high-density lipoprotein cholesterol (non-HDL-C), ve
114 w-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C).
116 es, low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol of, respectivel
117 sterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or low-density
118 nied by a proportional decrease in total and non-high-density lipoprotein cholesterol, plasma apolipo
119 rapy to decrease low-density lipoprotein and non-high-density lipoprotein cholesterol to specific tar
120 Plasma of PLSCR3(-/-) mice was elevated in non-high-density lipoproteins, cholesterol, triglyceride
121 n significantly greater reductions in LDL-C, non-high-density lipoprotein cholesterol, triglycerides,
122 protein (LDL) cholesterol up to 30% +/- 16%, non-high-density lipoprotein cholesterol up to 41% +/- 1
123 +/- 13%, LDL cholesterol up to 42% +/- 14%, non-high-density lipoprotein cholesterol up to 46% +/- 1
124 density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol; values below d
125 poproteins, the RR per 1-mmol/L reduction in non-high-density lipoprotein cholesterol was 0.79 (95% C
126 e US National Cholesterol Education Program, non-high-density lipoprotein cholesterol was introduced
127 cholesterol, CRP, apolipoprotein B-100, and non-high-density lipoprotein cholesterol were related to